Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Julio Montaner

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

HIV Infections

Chemicals & Drugs

Procedures

Geographic Areas

British Columbia

Concepts & Ideas

Living Beings

HIV-1

Activities & Behaviors

Physiology

Viral Drug Resistance

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Montaner Julio S G; Richman Douglas D; Hammer Scott M;
Poor agreement between 2 assays for measuring low levels of HIV-1 viral load.
Lima Viviane; Harrigan Richard; Montaner Julio S G
Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay.
Lima Viviane D; Harrigan Richard; Bangsberg David R; Hogg Robert S; Gross Robert; Yip Benita; Montaner Julio S G
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Julio Montaner (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Montaner Julio S G; Richman Douglas D; Hammer Scott M;
Poor agreement between 2 assays for measuring low levels of HIV-1 viral load.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2009;49(8):1283-4.
2009: Lima Viviane; Harrigan Richard; Montaner Julio S G
Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the Taqman assay in comparison to the Amplicor assay.
Journal of acquired immune deficiency syndromes (1999) 2009;51(1):3-6.
2009: Lima Viviane D; Harrigan Richard; Bangsberg David R; Hogg Robert S; Gross Robert; Yip Benita; Montaner Julio S G
The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time.
Journal of acquired immune deficiency syndromes (1999) 2009;50(5):529-36.
2009: Lima Viviane D; Fink Valeria; Yip Benita; Hogg Robert S; Harrigan P Richard; Montaner Julio S G
Association between HIV-1 RNA level and CD4 cell count among untreated HIV-infected individuals.
American journal of public health 2009;99 Suppl 1():S193-6.
2009: Rachlis Beth S; Wood Evan; Zhang Ruth; Montaner Julio S G; Kerr Thomas
High rates of homelessness among a cohort of street-involved youth.
Health & place 2009;15(1):10-7.
2009: Hull Mark W; Harris Marianne; Lima Viviane; Guillemi Silvia; Harrigan P Richard; Montaner Julio S G
Lopinavir/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation.
Journal of clinical pharmacology 2009;49(2):155-61.
2009: Lloyd-Smith Elisa; Wood Evan; Li Kathy; Montaner Julio S G; Kerr Thomas
Incidence and determinants of initiation into cocaine injection and correlates of frequent cocaine injectors.
Drug and alcohol dependence 2009;99(1-3):176-82.
2009: Shannon Kate; Kerr T; Strathdee S A; Shoveller J; Montaner J S; Tyndall M W
Prevalence and structural correlates of gender based violence among a prospective cohort of female sex workers.
BMJ (Clinical research ed.) 2009;339():b2939.
2009: Kim Christina; Kerr Thomas; Li Kathy; Zhang Ruth; Tyndall Mark W; Montaner Julio S G; Wood Evan
Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting.
BMC public health 2009;9():270.
2009: Kerr Thomas; Marshall Brandon D L; Miller Cari; Shannon Kate; Zhang Ruth; Montaner Julio S G; Wood Evan
Injection drug use among street-involved youth in a Canadian setting.
BMC public health 2009;9():171.
2009: Wood Evan; Kerr Thomas; Marshall Brandon D L; Li Kathy; Zhang Ruth; Hogg Robert S; Harrigan P Richard; Montaner Julio S G
Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study.
BMJ (Clinical research ed.) 2009;338():b1649.
2009: Kiboneka Andrew; Nyatia Ricky Jones; Nabiryo Christine; Anema Aranka; Cooper Curtis L; Fernandes Kimberly Ann; Montaner Julio S G; Mills Edward J
Combination antiretroviral therapy in population affected by conflict: outcomes from large cohort in northern Uganda.
BMJ (Clinical research ed.) 2009;338():b201.
2009: Marshall Brandon D L; Kerr Thomas; Shoveller Jean A; Montaner Julio S G; Wood Evan
Structural factors associated with an increased risk of HIV and sexually transmitted infection transmission among street-involved youth.
BMC public health 2009;9():7.
2008: Hull Mark W; Phillips Peter; Montaner Julio S G
Changing global epidemiology of pulmonary manifestations of HIV/AIDS.
Chest 2008;134(6):1287-98.
2008: Moore David M; Awor Anna; Downing Robert; Kaplan Jonathan; Montaner Julio S G; Hancock John; Were Willy; Mermin Jonathan
CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2008;49(5):477-84.
2008: Tam Lily W Y; Chui Celia K S; Brumme Chanson J; Bangsberg David R; Montaner Julio S G; Hogg Robert S; Harrigan P Richard
The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes.
Journal of acquired immune deficiency syndromes (1999) 2008;49(3):266-71.
2008: Fielden Sarah J; Rusch Melanie L A; Yip Benita; Wood Evan; Shannon Kate; Levy Adrian R; Montaner Julio S G; Hogg Robert S
Nonadherence increases the risk of hospitalization among HIV-infected antiretroviral naive patients started on HAART.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2008;7(5):238-44.
2008: Harris Marianne; Larsen Gerene; Montaner Julio S G
Exacerbation of depression associated with starting raltegravir: a report of four cases.
AIDS (London, England) 2008;22(14):1890-2.
2008: Hammer Scott M; Eron Joseph J; Reiss Peter; Schooley Robert T; Thompson Melanie A; Walmsley Sharon; Cahn Pedro; Fischl Margaret A; Gatell Jose M; Hirsch Martin S; Jacobsen Donna M; Montaner Julio S G; Richman Douglas D; Yeni Patrick G; Volberding Paul A;
Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 2008;300(5):555-70.
2008: Wood Evan; Hogg Robert S; Lima Viviane Dias; Kerr Thomas; Yip Benita; Marshall Brandon D L; Montaner Julio S G
Highly active antiretroviral therapy and survival in HIV-infected injection drug users.
JAMA : the journal of the American Medical Association 2008;300(5):550-4.
2008: Anema Aranka; Wood Evan; Montaner Julio S G
The use of highly active retroviral therapy to reduce HIV incidence at the population level.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2008;179(1):13-4.
2008: Hoda Zia; Kerr Thomas; Li Kathy; Montaner Julio S G; Wood Evan
Prevalence and correlates of jugular injections among injection drug users.
Drug and alcohol review 2008;27(4):442-6.
2008: Wood Evan; Kerr Thomas; Tyndall Mark W; Montaner Julio S G
A review of barriers and facilitators of HIV treatment among injection drug users.
AIDS (London, England) 2008;22(11):1247-56.
2008: Lima Viviane D; Johnston Karissa; Hogg Robert S; Levy Adrian R; Harrigan P Richard; Anema Aranka; Montaner Julio S G
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.
The Journal of infectious diseases 2008;198(1):59-67.
2008: Lima Viviane D; Gill Vikram S; Yip Benita; Hogg Robert S; Montaner Julio S G; Harrigan P Richard
Increased resilience to the development of drug resistance with modern boosted protease inhibitor-based highly active antiretroviral therapy.
The Journal of infectious diseases 2008;198(1):51-8.
2008: Kerr Thomas; Small William; Johnston Caitlin; Li Kathy; Montaner Julio S G; Wood Evan
Characteristics of injection drug users who participate in drug dealing: implications for drug policy.
Journal of psychoactive drugs 2008;40(2):147-52.
2008: Wood Evan; Kerr Thomas; Tyndall Mark W; Montaner Julio S G
The Canadian government's treatment of scientific process and evidence: inside the evaluation of North America's first supervised injecting facility.
The International journal on drug policy 2008;19(3):220-5.
2008: Harris Marianne; Larsen Gerene; Montaner Julio S G
Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen.
AIDS (London, England) 2008;22(10):1224-6.
2008: Wood R Alan; Wood Evan; Lai Calvin; Tyndall Mark W; Montaner Julio S G; Kerr Thomas
Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver's supervised injection facility.
The International journal on drug policy 2008;19(3):183-8.
2008: Wood Evan; Stoltz Jo-Anne; Zhang Ruth; Strathdee Steffanie A; Montaner Julio S G; Kerr Thomas
Circumstances of first crystal methamphetamine use and initiation of injection drug use among high-risk youth.
Drug and alcohol review 2008;27(3):270-6.
2008: Wood Evan; Montaner Julio S G
Antiretroviral therapy: a key part of the public health response to injection drug use.
Addiction (Abingdon, England) 2008;103(4):660-1.
2008: Joy Ruth; Druyts Eric F; Brandson Eirikka K; Lima Viviane D; Rustad Clare A; Zhang Wendy; Wood Evan; Montaner Julio S G; Hogg Robert S
Impact of neighborhood-level socioeconomic status on HIV disease progression in a universal health care setting.
Journal of acquired immune deficiency syndromes (1999) 2008;47(4):500-5.
2008: Wood Evan; Montaner Julio S G; Li Kathy; Zhang Ruth; Barney Lucy; Strathdee Steffanie A; Tyndall Mark W; Kerr Thomas
Burden of HIV infection among aboriginal injection drug users in Vancouver, British Columbia.
American journal of public health 2008;98(3):515-9.
2008: Phillips Elizabeth; Hayden Anna; Gutiérrez Sonia; Jahnke Natalie; Yip Benita; Lima Viviane D; Hogg Robert S; Harrigan P Richard; Montaner Julio S G
Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity: authors' reply.
AIDS (London, England) 2008;22(4):548-9.
2008: Low Andrew J; Marchant David; Brumme Chanson J; Brumme Zabrina L; Dong Winnie; Sing Tobias; Hogg Robert S; Montaner Julio S G; Gill Vikram; Cheung Peter K; Harrigan P Richard
CD4-dependent characteristics of coreceptor use and HIV type 1 V3 sequence in a large population of therapy-naive individuals.
AIDS research and human retroviruses 2008;24(2):219-28.
2008: Gutiérrez Sonia; Guillemi Silvia; Jahnke Natalie; Montessori Valentina; Harrigan P Richard; Montaner Julio S G
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(3):e28-30.
2008: Lloyd-Smith Elisa; Wood Evan; Zhang Ruth; Tyndall Mark W; Montaner Julio S G; Kerr Thomas
Risk factors for developing a cutaneous injection-related infection among injection drug users: a cohort study.
BMC public health 2008;8():405.
2007: Blades Ryan; Li Kathy; Kerr Thomas; Tyndall Mark W; Montaner Julio S G; Wood Evan
Contribution of HIV to mortality among injection drug users in the era of HAART.
Journal of acquired immune deficiency syndromes (1999) 2007;46(5):655-6.
2007: Loutfy M R; Harris M; Raboud J M; Antoniou T; Kovacs C; Shen S; Dufresne S; Smaill F; Rouleau D; Rachlis A; Gough K; Lalonde R; Tsoukas C; Trottier B; Walmsley S L; Montaner J S G
A large prospective study assessing injection site reactions, quality of life and preference in patients using the Biojector vs standard needles for enfuvirtide administration.
HIV medicine 2007;8(7):427-32.
2007: Wood Evan; Kerr Thomas; Tyndall Mark W; Zhang Ruth; Hogg Robert S; Strathdee Steffanie A; Montaner Julio S G
Rates of HIV/AIDS care and antiretroviral therapy response among active injection drug users.
Addiction (Abingdon, England) 2007;102(9):1503-5.
2007: Stoltz Jo-Anne Madeleine; Shannon Kate; Kerr Thomas; Zhang Ruth; Montaner Julio S; Wood Evan
Associations between childhood maltreatment and sex work in a cohort of drug-using youth.
Social science & medicine (1982) 2007;65(6):1214-21.
2007: Reynes Jacques; Arastéh Keikawus; Clotet Bonaventura; Cohen Calvin; Cooper David A; Delfraissy Jean-François; Eron Joseph J; Henry Keith; Katlama Christine; Kuritzkes Daniel R; Lalezari Jacob P; Lange Joep; Lazzarin Adriano; Montaner Julio S G; Nelson Mark; O' Hearn Mary; Stellbrink Hans-Jürgen; Trottier Benoit; Walmsley Sharon L; Buss Neil E; Demasi Ralph; Chung Jain; Donatacci Lucille; Guimaraes Denise; Rowell Lucy; Valentine Adeline; Wilkinson Martin; Salgo Miklos P
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
AIDS patient care and STDs 2007;21(8):533-43.
2007: Hull Mark; Harris Marianne; Montaner Julio S G
Stopping antiretroviral therapy: easier said than done.
AIDS (London, England) 2007;21(13):1817-8.
2007: Phillips Elizabeth; Gutiérrez Sonia; Jahnke Natalie; Yip Benita; Lima Viviane D; Hogg Robert S; Harrigan P Richard; Montaner Julio S G
Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
AIDS (London, England) 2007;21(12):1561-8.
2007: Wood Evan; Kerr Thomas; Montaner Julio S G
HIV treatment, injection drug use, and illicit drug policies.
Lancet 2007;370(9581):8-10.
2007: Brumme Zabrina L; Brumme Chanson J; Heckerman David; Korber Bette T; Daniels Marcus; Carlson Jonathan; Kadie Carl; Bhattacharya Tanmoy; Chui Celia; Szinger James; Mo Theresa; Hogg Robert S; Montaner Julio S G; Frahm Nicole; Brander Christian; Walker Bruce D; Harrigan P Richard
Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1.
PLoS pathogens 2007;3(7):e94.
2007: Wood Evan; Montaner Julio S; Li Kathy; Barney Lucy; Tyndall Mark W; Kerr Thomas
Rate of methadone use among Aboriginal opioid injection drug users.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2007;177(1):37-40.
2007: Tam L W Y; Hogg R S; Yip B; Montaner J S G; Harrigan P R; Brumme C J
Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
HIV medicine 2007;8(5):267-70.
2007: Kerr Thomas; Tyndall Mark W; Zhang Ruth; Lai Calvin; Montaner Julio S G; Wood Evan
Circumstances of first injection among illicit drug users accessing a medically supervised safer injection facility.
American journal of public health 2007;97(7):1228-30.
2007: Loutfy M R; Raboud J M; Montaner J S G; Antoniou T; Wynhoven B; Smaill F; Rouleau D; Gill J; Schlech W; Brumme Z L; Mo T; Gough K; Rachlis A; Harrigan P R; Walmsley S L
Assay of HIV gp41 amino acid sequence to identify baseline variation and mutation development in patients with virologic failure on enfuvirtide.
Antiviral research 2007;75(1):58-63.
2007: Nelson Mark R; Katlama Christine; Montaner Julio S; Cooper David A; Gazzard Brian; Clotet Bonaventura; Lazzarin Adriano; Schewe Knud; Lange Joep; Wyatt Christina; Curtis Sue; Chen Shan-Shan; Smith Stephen; Bischofberger Norbert; Rooney James F
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
AIDS (London, England) 2007;21(10):1273-81.
2007: Wood Evan; Montaner Julio S G
When to initiate HIV antiretroviral therapy: do benefits other than survival deserve greater attention?
Journal of acquired immune deficiency syndromes (1999) 2007;45(2):131-2.
2007: Wood Evan; Tyndall Mark W; Zhang Ruth; Montaner Julio S G; Kerr Thomas
Rate of detoxification service use and its impact among a cohort of supervised injecting facility users.
Addiction (Abingdon, England) 2007;102(6):916-9.
2007: Chui Celia K S; Brumme Zabrina L; Brumme Chanson J; Yip Benita; Phillips Elizabeth J; Montaner Julio S G; Harrigan P Richard
A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;44(11):1503-8.
2007: Brumme Zabrina L; Brumme Chanson J; Chui Celia; Mo Theresa; Wynhoven Brian; Woods Conan K; Henrick Bethany M; Hogg Robert S; Montaner Julio S G; Harrigan P Richard
Effects of human leukocyte antigen class I genetic parameters on clinical outcomes and survival after initiation of highly active antiretroviral therapy.
The Journal of infectious diseases 2007;195(11):1694-704.
2007: Maas Benjamin; Fairbairn Nadia; Kerr Thomas; Li Kathy; Montaner Julio S G; Wood Evan
Neighborhood and HIV infection among IDU: place of residence independently predicts HIV infection among a cohort of injection drug users.
Health & place 2007;13(2):432-9.
2007: Ezzat H; Filipenko D; Vickars L; Galbraith P; Li C; Murphy K; Montaner J S G; Harris M; Hogg R S; Vercauteren S; Leger C S; Zypchen L; Leitch H A
Improved survival in HIV-associated diffuse large B-cell lymphoma with the addition of rituximab to chemotherapy in patients receiving highly active antiretroviral therapy.
HIV clinical trials 2007;8(3):132-44.
2007: Lima Viviane D; Geller Josie; Bangsberg David R; Patterson Thomas L; Daniel Mark; Kerr Thomas; Montaner Julio S G; Hogg Robert S
The effect of adherence on the association between depressive symptoms and mortality among HIV-infected individuals first initiating HAART.
AIDS (London, England) 2007;21(9):1175-83.
2007: Fairbairn Nadia; Kerr Thomas; Buxton Jane A; Li Kathy; Montaner Julio S; Wood Evan
Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting.
Drug and alcohol dependence 2007;88(2-3):313-6.
2007: Petrar Steven; Kerr Thomas; Tyndall Mark W; Zhang Ruth; Montaner Julio S G; Wood Evan
Injection drug users' perceptions regarding use of a medically supervised safer injecting facility.
Addictive behaviors 2007;32(5):1088-93.
2007: Montaner Julio S G; Hogg Robert S
Hungering for HAART.
Annals of internal medicine 2007;146(8):609-10.
2007: Christie Timothy; Asrat Getnet A; Jiwani Bashir; Maddix Thomas; Montaner Julio S G
Exploring disparities between global HIV/AIDS funding and recent tsunami relief efforts: an ethical analysis.
Developing world bioethics 2007;7(1):1-7.
2007: Lima Viviane D; Hogg Robert S; Harrigan P Richard; Moore David; Yip Benita; Wood Evan; Montaner Julio S G
Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy.
AIDS (London, England) 2007;21(6):685-92.
2007: Wood E; Hogg R S; Yip B; Moore D; Harrigan P R; Montaner J S G
Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme.
HIV medicine 2007;8(2):80-5.
2007: Lima Viviane D; Hogg Robert S; Montaner Julio S G
Presenting plasma HIV RNA level and rate of CD4 T-cell decline.
JAMA : the journal of the American Medical Association 2007;297(8):805-6; author reply 806-7.
2007: Wood Evan; Lloyd-Smith Elisa; Li Kathy; Strathdee Steffanie A; Small Will; Tyndall Mark W; Montaner Julio S G; Kerr Thomas
Frequent needle exchange use and HIV incidence in Vancouver, Canada.
The American journal of medicine 2007;120(2):172-9.
2007: Montaner Julio S G
Modern highly active antiretroviral therapy-a very well tuned compass for a rapidly evolving field.
Enfermedades infecciosas y microbiología clínica 2007;25(1):1-2.
2007: Brumme Chanson J; Harrigan P Richard; Preston Emma C; Dong Winnie W Y; Wynhoven Brian; Murphy Carol; Montaner Julio S G
Transmission of drug-resistant HIV-1 from an infected individual to a caregiver.
Antiviral therapy 2007;12(7):1139-44.
2007: McKnight Ian; Maas Ben; Wood Evan; Tyndall Mark W; Small Will; Lai Calvin; Montaner Julio S G; Kerr Thomas
Factors associated with public injecting among users of Vancouver's supervised injection facility.
The American journal of drug and alcohol abuse 2007;33(2):319-25.
2007: Wood Evan; Hogg Robert S; Kerr Thomas; Bonner Simon; Strathdee Steffanie A; Palepu Anita; Montaner Julio S G
Rates of inappropriate antiretroviral prescription among injection drug users.
Harm reduction journal 2007;4():2.
2006: Alfonso Victoria; Bermbach Nicole; Geller Josie; Montaner Julio S G
Individual variability in barriers affecting people's decision to take HAART: a qualitative study identifying barriers to being on HAART.
AIDS patient care and STDs 2006;20(12):848-57.
2006: Moore David M; Mermin Jonathan; Awor Anna; Yip Benita; Hogg Robert S; Montaner Julio S G
Performance of immunologic responses in predicting viral load suppression: implications for monitoring patients in resource-limited settings.
Journal of acquired immune deficiency syndromes (1999) 2006;43(4):436-9.
2006: Christie Timothy K S; Harris Marianne; Montaner Julio S G
Special Access Denied: A Case Study of Health Canada's Special Access Program.
Healthcare policy = Politiques de santé 2006;2(2):27-34.
2006: Wood Evan; Tyndall Mark W; Montaner Julio S; Kerr Thomas
Summary of findings from the evaluation of a pilot medically supervised safer injecting facility.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2006;175(11):1399-404.
2006: Dhalla Shayesta; Chan Keith J; Montaner Julio S G; Hogg Robert S
Complementary and alternative medicine use in British Columbia--a survey of HIV positive people on antiretroviral therapy.
Complementary therapies in clinical practice 2006;12(4):242-8.
2006: Miller C L; Spittal P M; Wood E; Chan K; Schechter M T; Montaner J S G; Hogg R S
Inadequacies in antiretroviral therapy use among Aboriginal and other Canadian populations.
AIDS care 2006;18(8):968-76.
2006: Gross Robert; Yip Benita; Lo Re Vincent; Wood Evan; Alexander Christopher S; Harrigan P Richard; Bangsberg David R; Montaner Julio S G; Hogg Robert S
A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression.
The Journal of infectious diseases 2006;194(8):1108-14.
2006: Braitstein P; Li K; Kerr T; Montaner J S G; Hogg R S; Wood E
Differences in access to care among injection drug users infected either with HIV and hepatitis C or hepatitis C alone.
AIDS care 2006;18(7):690-3.
2006: Hogg Robert S; Bangsberg David R; Lima Viviane D; Alexander Chris; Bonner Simon; Yip Benita; Wood Evan; Dong Winnie W Y; Montaner Julio S G; Harrigan P Richard
Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART.
PLoS medicine 2006;3(9):e356.
2006: Wood Evan; Kerr Thomas; Hogg Robert S; Palepu Anita; Zhang Ruth; Strathdee Steffanie A; Montaner Julio S G
Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users.
Drug and alcohol review 2006;25(5):451-4.
2006: Moore D M; Hogg R S; Yip B; Craib K; Wood E; Montaner J S G
CD4 percentage is an independent predictor of survival in patients starting antiretroviral therapy with absolute CD4 cell counts between 200 and 350 cells/microL.
HIV medicine 2006;7(6):383-8.
2006: Palepu Anita; Tyndall Mark W; Joy Ruth; Kerr Thomas; Wood Evan; Press Natasha; Hogg Robert S; Montaner Julio S G
Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy.
Drug and alcohol dependence 2006;84(2):188-94.
2006: Hammer Scott M; Saag Michael S; Schechter Mauro; Montaner Julio S G; Schooley Robert T; Jacobsen Donna M; Thompson Melanie A; Carpenter Charles C J; Fischl Margaret A; Gazzard Brian G; Gatell Jose M; Hirsch Martin S; Katzenstein David A; Richman Douglas D; Vella Stefano; Yeni Patrick G; Volberding Paul A;
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society--USA panel.
Topics in HIV medicine : a publication of the International AIDS Society, USA 2006;14(3):827-43.
2006: Hammer Scott M; Saag Michael S; Schechter Mauro; Montaner Julio S G; Schooley Robert T; Jacobsen Donna M; Thompson Melanie A; Carpenter Charles C J; Fischl Margaret A; Gazzard Brian G; Gatell Jose M; Hirsch Martin S; Katzenstein David A; Richman Douglas D; Vella Stefano; Yeni Patrick G; Volberding Paul A;
Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 2006;296(7):827-43.
2006: Montaner Julio S G; Hogg Robert; Wood Evan; Kerr Thomas; Tyndall Mark; Levy Adrian R; Harrigan P Richard
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.
Lancet 2006;368(9534):531-6.
2006: Moore D M; Hogg R S; Yip B; Wood E; Harris M; Montaner J S G
Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
HIV medicine 2006;7(5):311-6.
2006: Chui Celia; Cheung Peter K; Brumme Chanson J; Mo Theresa; Brumme Zabrina L; Montaner Julio S G; Badley Andrew D; Harrigan P Richard
HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy.
AIDS research and human retroviruses 2006;22(7):615-8.
2006: Côté Hélène C F; Brumme Zabrina L; Chan Jennifer W; Guillemi Silvia; Montaner Julio S G; Harrigan P Richard
HIV therapy, hepatitis C virus infection, antibiotics and obesity, a mitochondria killer mix?
AIDS (London, England) 2006;20(9):1343-5.
2006: Wood Evan; Tyndall Mark W; Zhang Ruth; Stoltz Jo-Anne; Lai Calvin; Montaner Julio S G; Kerr Thomas
Attendance at supervised injecting facilities and use of detoxification services.
The New England journal of medicine 2006;354(23):2512-4.
2006: Christie Timothy K S; Montaner Julio S G
The perverted irony of Health Canada's Special Access Programme.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2006;174(12):1746.
2006: Alfonso Victoria; Geller Josie; Bermbach Nicole; Drummond Anne; Montaner Julio S G
Becoming a "treatment success": what helps and what hinders patients from achieving and sustaining undetectable viral loads.
AIDS patient care and STDs 2006;20(5):326-34.
2006: Wood Evan; Hogg Robert S; Yip Benita; Moore David; Harrigan P Richard; Montaner Julio S G
Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
AIDS (London, England) 2006;20(8):1117-23.
2006: Wood Evan; Stoltz Jo-Anne; Li Kathy; Montaner Julio S G; Kerr Thomas
Changes in Canadian heroin supply coinciding with the Australian heroin shortage.
Addiction (Abingdon, England) 2006;101(5):689-95.
2006: Wood Evan; Tyndall Mark W; Qui Zhenguo; Zhang Ruth; Montaner Julio S G; Kerr Thomas
Service uptake and characteristics of injection drug users utilizing North America's first medically supervised safer injecting facility.
American journal of public health 2006;96(5):770-3.
2006: Wood Evan; Kerr Thomas; Hogg Robert S; Zhang Ruth; Tyndall Mark W; Montaner Julio S G
Validity of self-reported antiretroviral therapy use among injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2006;41(4):530-1.
2006: Wood Evan; Kerr Thomas; Palepu Anita; Zhang Ruth; Strathdee Steffanie A; Tyndall Mark W; Montaner Julio S G; Hogg Robert S
Slower uptake of HIV antiretroviral therapy among Aboriginal injection drug users.
The Journal of infection 2006;52(4):233-6.
2006: Harris Marianne; Larsen Gerene; Valyi Monica; Walker Ekaterina; Montaner Julio S G
Transient neuropathy after needle-free injection outside of recommended sites.
AIDS (London, England) 2006;20(5):784-5.
2006: Harris Marianne; Joy Ruth; Larsen Gerene; Valyi Monica; Walker Ekaterina; Frick Lloyd W; Palmatier Robin M; Wring Stephen A; Montaner Julio Sg
Enfuvirtide plasma levels and injection site reactions using a needle-free gas-powered injection system (Biojector).
AIDS (London, England) 2006;20(5):719-23.
2006: Levy Adrian R; James Douglas; Johnston Karissa M; Hogg Robert S; Harrigan P Richard; Harrigan Brian P; Sobolev Boris; Montaner Julio S
The direct costs of HIV/AIDS care.
The Lancet infectious diseases 2006;6(3):171-7.
2006: Lloyd-Smith Elisa; Brodkin Elizabeth; Wood Evan; Kerr Thomas; Tyndall Mark W; Montaner Julio S G; Hogg Robert S
Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
AIDS (London, England) 2006;20(3):445-50.
2006: Moore David M; Hogg Robert S; Chan Keith; Tyndall Mark; Yip Benita; Montaner Julio S G
Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
AIDS (London, England) 2006;20(3):371-7.
2006: Braitstein Paula; Justice Amy; Bangsberg David R; Yip Benita; Alfonso Victoria; Schechter Martin T; Hogg Robert S; Montaner Julio S G
Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort.
AIDS (London, England) 2006;20(3):323-31.
2006: Spittal P M; Hogg R S; Li K; Craib K J; Recsky M; Johnston C; Montaner J S G; Schechter M T; Wood E
Drastic elevations in mortality among female injection drug users in a Canadian setting.
AIDS care 2006;18(2):101-8.
2006: Braitstein Paula; Zala Carlos; Yip Benita; Brinkhof Martin W G; Moore David; Hogg Robert S; Montaner Julio S G
Immunologic response to antiretroviral therapy in hepatitis C virus-coinfected adults in a population-based HIV/AIDS treatment program.
The Journal of infectious diseases 2006;193(2):259-68.
2006: Kerr Thomas; Stoltz Jo-Anne; Strathdee Steffanie; Li Kathy; Hogg Robert S; Montaner Julio S; Wood Evan
The impact of sex partners' HIV status on HIV seroconversion in a prospective cohort of injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2006;41(1):119-23.
2006: Tyndall Mark W; Wood Evan; Zhang Ruth; Lai Calvin; Montaner Julio S G; Kerr Thomas
HIV seroprevalence among participants at a Supervised Injection Facility in Vancouver, Canada: implications for prevention, care and treatment.
Harm reduction journal 2006;3():36.
2006: Montaner Julio S G; Schutz Malte; Schwartz Robert; Jayaweera Dushyantha T; Burnside Alfred F; Walmsley Sharon; Saag Michael S
Efficacy, safety and pharmacokinetics of once-daily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients.
MedGenMed : Medscape general medicine 2006;8(2):36.
2006: Kuyper Laura M; Kerr Thomas; Li Kathy; Hogg Robert S; Tyndall Mark W; Montaner Julio S G; Wood Evan
Factors associated with buying and selling syringes among injection drug users in a setting of one of North America's largest syringe exchange programs.
Substance use & misuse 2006;41(6-7):883-99.
2006: Wood Evan; Stoltz Jo-Anne; Montaner Julio S G; Kerr Thomas
Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study.
Harm reduction journal 2006;3():18.
2006: Lima Viviane D; Kretz Patricia; Palepu Anita; Bonner Simon; Kerr Thomas; Moore David; Daniel Mark; Montaner Julio S G; Hogg Robert S
Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART.
AIDS research and therapy 2006;3():14.
2006: Wood Evan; Tyndall Mark W; Lai Calvin; Montaner Julio S G; Kerr Thomas
Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime.
Substance abuse treatment, prevention, and policy 2006;1():13.
2006: Moore David M; Hogg Robert S; Braitstein Paula; Wood Evan; Yip Benito; Montaner Julio S G
Risks of non-accidental mortality by baseline CD4+ T-cell strata in hepatitis-C-positive and -negative individuals initiating highly active antiretroviral therapy.
Antiviral therapy 2006;11(1):125-9.
2006: Côté Hélène C F; Magil Alex B; Harris Marianne; Scarth Brian J; Gadawski Izabelle; Wang Nancy; Yu Eugenia; Yip Benita; Zalunardo Nadia; Werb Ron; Hogg Robert; Harrigan P Richard; Montaner Julio S
Exploring mitochondrial nephrotoxicity as a potential mechanism of kidney dysfunction among HIV-infected patients on highly active antiretroviral therapy.
Antiviral therapy 2006;11(1):79-86.
2005: Nelson Mark; Arastéh Keikawus; Clotet Bonaventura; Cooper David A; Henry Keith; Katlama Christine; Lalezari Jacob P; Lazzarin Adriano; Montaner Julio S G; O'Hearn Mary; Piliero Peter J; Reynes Jacques; Trottier Benoit; Walmsley Sharon L; Cohen Calvin; Eron Joseph J; Kuritzkes Daniel R; Lange Joep; Stellbrink Hans-Jürgen; Delfraissy Jean-François; Buss Neil E; Donatacci Lucille; Wat Cynthia; Smiley Lynn; Wilkinson Martin; Valentine Adeline; Guimaraes Denise; Demasi Ralph; Chung Jain; Salgo Miklos P
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Journal of acquired immune deficiency syndromes (1999) 2005;40(4):404-12.
2005: Wood E; Kerr T; Stoltz J; Qui Z; Zhang R; Montaner J S G; Tyndall M W
Prevalence and correlates of hepatitis C infection among users of North America's first medically supervised safer injection facility.
Public health 2005;119(12):1111-5.
2005: Lloyd-Smith Elisa; Kerr Thomas; Hogg Robert S; Li Kathy; Montaner Julio S G; Wood Evan
Prevalence and correlates of abscesses among a cohort of injection drug users.
Harm reduction journal 2005;2():24.
2005: Moore David M; Hogg Robert S; Yip Benita; Wood Evan; Tyndall Mark; Braitstein Paula; Montaner Julio S G
Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy.
Journal of acquired immune deficiency syndromes (1999) 2005;40(3):288-93.
2005: Toulson Adrienne R; Harrigan Richard; Heath Katherine; Yip Benita; Brumme Zabrina L; Harris Marianne; Hogg Robert S; Montaner Julio S G
Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.
The Journal of infectious diseases 2005;192(10):1787-93.
2005: Collins Courtney L C; Kerr Thomas; Tyndall Mark W; Marsh David C; Kretz Patricia S; Montaner Julio S; Wood Evan
Rationale to evaluate medically supervised safer smoking facilities for non-injection illicit drug users.
Canadian journal of public health. Revue canadienne de santé publique 2005;96(5):344-7.
2005: O'Connell Jacqueline M; Kerr Thomas; Li Kathy; Tyndall Mark W; Hogg Robert S; Montaner Julio S; Wood Evan
Requiring help injecting independently predicts incident HIV infection among injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2005;40(1):83-8.
2005: Lem Marcus; Moore David; Marion Stephen; Bonner Simon; Chan Keith; O'Connell Jacqueline; Montaner Julio S G; Hogg Robert
Back to work: correlates of employment among persons receiving highly active antiretroviral therapy.
AIDS care 2005;17(6):740-6.
2005: Wood Evan; Tyndall Mark W; Li Kathy; Lloyd-Smith Elisa; Small Will; Montaner Julio S G; Kerr Thomas
Do supervised injecting facilities attract higher-risk injection drug users?
American journal of preventive medicine 2005;29(2):126-30.
2005: Brumme Zabrina L; Goodrich James; Mayer Howard B; Brumme Chanson J; Henrick Bethany M; Wynhoven Brian; Asselin Jerome J; Cheung Peter K; Hogg Robert S; Montaner Julio S G; Harrigan P Richard
Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals.
The Journal of infectious diseases 2005;192(3):466-74.
2005: Kuyper Laura M; Collins Courtney Lc; Kerr Thomas; Hogg Robert S; Li Kathy; Tyndall Mark W; Montaner Julio Sg; Wood Evan
The prevalence and incidence of sexually transmitted infections in a prospective cohort of injection drug users in Vancouver, British Columbia.
The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie médicale / AMMI Canada 2005;16(4):225-9.
2005: Shannon Kate; Kerr Thomas; Lai Calvin; Ishida Tomiye; Wood Evan; Montaner Julio S G; Hogg Robert S; Tyndall Mark W
Nonadherence to antiretroviral therapy among a community with endemic rates of injection drug use.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 2005;4(3):66-72.
2005: Braitstein Paula; Yip Benita; Montessori Valentina; Moore David; Montaner Julio S G; Hogg Robert S
Effect of serostatus for hepatitis C virus on mortality among antiretrovirally naive HIV-positive patients.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2005;173(2):160-4.
2005: Wood Evan; Hogg Robert S; Yip Benita; Dong Winnie W Y; Wynhoven Brian; Mo Theresa; Brumme Chanson J; Montaner Julio S G; Harrigan P Richard
Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use.
AIDS (London, England) 2005;19(11):1189-95.
2005: Wood Evan; Hogg Robert S; Harrigan P Richard; Montaner Julio S G
When to initiate antiretroviral therapy in HIV-1-infected adults: a review for clinicians and patients.
The Lancet infectious diseases 2005;5(7):407-14.
2005: Collins Courtney L C; Kerr Thomas; Kuyper Laura M; Li Kathy; Tyndall Mark W; Marsh David C; Montaner Julio S; Wood Evan
Potential uptake and correlates of willingness to use a supervised smoking facility for noninjection illicit drug use.
Journal of urban health : bulletin of the New York Academy of Medicine 2005;82(2):276-84.
2005: Braitstein P; Montessori V; Chan K; Montaner J S G; Schechter M T; O'Shaughnessy M V; Hogg R S
Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort.
AIDS care 2005;17(4):505-15.
2005: Wood Evan; Hogg Robert S; Kerr Thomas; Palepu Anita; Zhang Ruth; Montaner Julio S G
Impact of accessing methadone on the time to initiating HIV treatment among antiretroviral-naive HIV-infected injection drug users.
AIDS (London, England) 2005;19(8):837-9.
2005: Normén Lena; Chan Keith; Braitstein Paula; Anema Aranka; Bondy Greg; Montaner Julio S G; Hogg Robert S
Food insecurity and hunger are prevalent among HIV-positive individuals in British Columbia, Canada.
The Journal of nutrition 2005;135(4):820-5.
2005: Harrigan P Richard; Wynhoven Brian; Brumme Zabrina L; Brumme Chanson J; Sattha Beheroze; Major Jennifer C; de la Rosa Rafael; Montaner Julio S G
HIV-1 drug resistance: degree of underestimation by a cross-sectional versus a longitudinal testing approach.
The Journal of infectious diseases 2005;191(8):1325-30.
2005: Wood Evan; Li Kathy; Small Will; Montaner Julio S; Schechter Martin T; Kerr Thomas
Recent incarceration independently associated with syringe sharing by injection drug users.
Public health reports (Washington, D.C. : 1974) 2005;120(2):150-6.
2005: Zala Carlos; Alexander Christopher S; Ochoa Claudia; Guillemi Silvia; Ting Lillian S; Bonner Simon; Cahn Pedro; Harrigan P Richard; Montaner Julio S G
Comparable pharmacokinetics of generic indinavir (Inhibisam) versus brand indinavir (Crixivan) when boosted with ritonavir.
Journal of acquired immune deficiency syndromes (1999) 2005;38(3):363-4.
2005: van Leth Frank; Huisamen Casper B; Badaro Roberto; Vandercam Bernard; de Wet Joss; Montaner Julio S G; Hall David B; Wit Ferdinand W N M; Lange Joep M A;
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
Journal of acquired immune deficiency syndromes (1999) 2005;38(3):296-300.
2005: Wood Evan; Hogg Robert S; Yip Benita; Harrigan P Richard; Montaner Julio S G
Why are baseline HIV RNA levels 100,000 copies/mL or greater associated with mortality after the initiation of antiretroviral therapy?
Journal of acquired immune deficiency syndromes (1999) 2005;38(3):289-95.
2005: Harrigan P Richard; Hogg Robert S; Dong Winnie W Y; Yip Benita; Wynhoven Brian; Woodward Justin; Brumme Chanson J; Brumme Zabrina L; Mo Theresa; Alexander Chris S; Montaner Julio S G
Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.
The Journal of infectious diseases 2005;191(3):339-47.
2005: Wood Evan; Li Kathy; Miller Cari L; Hogg Robert S; Montaner Julio S G; Schechter Martin T; Kerr Thomas
Baseline self-perceived risk of HIV infection independently predicts the rate of HIV seroconversion in a prospective cohort of injection drug users.
International journal of epidemiology 2005;34(1):152-8.
2005: Brumme Zabrina L; Henrick Bethany M; Brumme Chanson J; Hogg Robert S; Montaner Julio S G; Harrigan P Richard
Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
Antiviral therapy 2005;10(7):849-53.
2005: Wood Evan; Li Kathy; Palepu Anita; Marsh David C; Schechter Martin T; Hogg Robert S; Montaner Julio S G; Kerr Thomas
Sociodemographic disparities in access to addiction treatment among a cohort of Vancouver injection drug users.
Substance use & misuse 2005;40(8):1153-67.
2005: Wainberg Mark A; Sawyer James P C; Montaner Julio S G; Murphy Robert L; Kuritzkes Daniel R; Raffi Francois
Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
Antiviral therapy 2005;10(1):13-28.
2005: Levy Adrian R; McCandless Lawrence; Harrigan P Richard; Hogg Robert S; Bondy Greg; Iloeje Uchenna H; Mukherjee Jayanti; Montaner Julio S
Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.
Lipids in health and disease 2005;4():4.
2004: Wood Evan; Hogg Robert S; Yip Benita; Harrigan P Richard; Montaner Julio S G
Earlier initiation of highly active antiretroviral therapy does not protect against the deleterious effects of non-adherence.
AIDS (London, England) 2004;18(18):2432-4.
2004: Kuyper Laura M; Wood Evan; Montaner Julio S G; Yip Benita; O'connell Jacqueline M; Hogg Robert S
Gender differences in HIV-1 RNA rebound attributed to incomplete antiretroviral adherence among HIV-Infected patients in a population-based cohort.
Journal of acquired immune deficiency syndromes (1999) 2004;37(4):1470-6.
2004: Kuyper Laura M; Hogg Robert S; Montaner Julio S G; Schechter Martin T; Wood Evan
The cost of inaction on HIV transmission among injection drug users and the potential for effective interventions.
Journal of urban health : bulletin of the New York Academy of Medicine 2004;81(4):655-60.
2004: Braitstein Paula; Palepu Anita; Dieterich Douglas; Benhamou Yves; Montaner Julio S G
Special considerations in the initiation and management of antiretroviral therapy in individuals coinfected with HIV and hepatitis C.
AIDS (London, England) 2004;18(17):2221-34.
2004: Kerr Thomas; Wodak Alex; Elliott Richard; Montaner Julio S; Wood Evan
Opioid substitution and HIV/AIDS treatment and prevention.
Lancet 2004;364(9449):1918-9.
2004: Quarleri Jorge F; Rubio Andrea; Carobene Mauricio; Turk Gabriela; Vignoles Moira; Harrigan Richard P; Montaner Julio S G; Salomón Horacio; Gómez-Carrillo Manuel
HIV type 1 BF recombinant strains exhibit different pol gene mosaic patterns: descriptive analysis from 284 patients under treatment failure.
AIDS research and human retroviruses 2004;20(10):1100-7.
2004: Palepu Anita; Tyndall Mark W; Chan Keith; Wood Evan; Montaner Julio S G; Hogg Robert S
Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
Antiviral therapy 2004;9(5):713-9.
2004: Alexander Christopher S; Montaner Julio S G; Asselin Jérôme J; Ting Lillian; McNabb Kelly; Harris Marianne; Guillemi Silvia; Harrigan P Richard
Simplification of therapeutic drug monitoring for twice-daily regimens of lopinavir/ritonavir for HIV infection.
Therapeutic drug monitoring 2004;26(5):516-23.
2004: Harris Marianne; Montaner Julio S G
Management of HIV-infected patients with multidrug-resistant virus.
Current HIV/AIDS reports 2004;1(3):116-21.
2004: Wood Evan; Kerr Thomas; Small Will; Li Kathy; Marsh David C; Montaner Julio S G; Tyndall Mark W
Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2004;171(7):731-4.
2004: Wood Evan; Hogg Robert S; Bonner Simon; Kerr Thomas; Li Kathy; Palepu Anita; Guillemi Silvia; Schechter Martin T; Montaner Julio S G
Staging for antiretroviral therapy among HIV-infected drug users.
JAMA : the journal of the American Medical Association 2004;292(10):1175-7.
2004: Loutfy Mona R; Raboud Janet M; Walmsley Sharon L; Saskin Refik; Montaner Julio S; Hogg Robert S; Thompson Courtney A; Harrigan P Richard
Predictive value of HIV-1 protease genotype and virtual phenotype on the virological response to lopinavir/ritonavir-containing salvage regimens.
Antiviral therapy 2004;9(4):595-602.
2004: Yeni Patrick G; Hammer Scott M; Hirsch Martin S; Saag Michael S; Schechter Mauro; Carpenter Charles C J; Fischl Margaret A; Gatell Jose M; Gazzard Brian G; Jacobsen Donna M; Katzenstein David A; Montaner Julio S G; Richman Douglas D; Schooley Robert T; Thompson Melanie A; Vella Stefano; Volberding Paul A
Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2004;292(2):251-65.
2004: Recsky Magdalena A; Brumme Zabrina L; Chan Keith J; Wynhoven Brian; Yip Benita; Dong Winnie W Y; Heath Katherine V; Montaner Julio S G; Levy Adrian R; Hogg Robert S; Harrigan P Richard
Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.
The Journal of infectious diseases 2004;190(2):285-92.
2004: King Martin S; Bernstein Barry M; Walmsley Sharon L; Sherer Renslow; Feinberg Judith; Sanne Ian; Cernohous Paul; Montaner Julio S G; Brun Scott C; Sun Eugene
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
The Journal of infectious diseases 2004;190(2):280-4.
2004: Wood Evan; Spittal Patricia; Li Kathy; Kerr Thomas; Miller Cari L; Hogg Robert S; Montaner Julio S G; Schechter Martin T
Inability to access addiction treatment and risk of HIV infection among injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2004;36(2):750-4.
2004: Miller Cari L; Wood Evan; Spittal Patricia M; Li Kathy; Frankish James C; Braitstein Paula; Montaner Julio S G; Schechter Martin T
The future face of coinfection: prevalence and incidence of HIV and hepatitis C virus coinfection among young injection drug users.
Journal of acquired immune deficiency syndromes (1999) 2004;36(2):743-9.
2004: Press Natasha M; Montaner Julio S G; Bondy Gregory
Resolution of diabetes after initiation of antiretroviral therapy in two human immunodeficiency virus-infected patients.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2004;10(3):199-202.
2004: Castillo E; Palepu A; Beardsell A; Akagi L; Yip B; Montaner J S G; Hogg R S
Outpatient pharmacy care and HIV viral load response among patients on HAART.
AIDS care 2004;16(4):446-57.
2004: Wood Evan; Spittal Patricia M; Small Will; Kerr Thomas; Li Kathy; Hogg Robert S; Tyndall Mark W; Montaner Julio S G; Schechter Martin T
Displacement of Canada's largest public illicit drug market in response to a police crackdown.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2004;170(10):1551-6.
2004: Wood Evan; Kerr Thomas; Montaner Julio S; Strathdee Steffanie A; Wodak Alex; Hankins Catherine A; Schechter Martin T; Tyndall Mark W
Rationale for evaluating North America's first medically supervised safer-injecting facility.
The Lancet infectious diseases 2004;4(5):301-6.
2004: Wood Evan; Montaner Julio S G; Yip Benita; Tyndall Mark W; Schechter Martin T; O'Shaughnessy Michael V; Hogg Robert S
Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users.
Antiviral therapy 2004;9(2):229-35.
2004: Wood Evan; Hogg Robert S; Yip Benita; Harrigan P Richard; Montaner Julio S G
Using baseline CD4 cell count and plasma HIV RNA to guide the initiation of highly active antiretroviral therapy.
Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición 2004;56(2):232-6.
2004: Brumme Zabrina L; Dong Winnie W Y; Yip Benita; Wynhoven Brian; Hoffman Noah G; Swanstrom Ronald; Jensen Mark A; Mullins James I; Hogg Robert S; Montaner Julio S G; Harrigan P Richard
Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy.
AIDS (London, England) 2004;18(4):F1-9.
2004: Wood Evan; Hogg Robert S; Yip Benita; Harrigan P Richard; O'Shaughnessy Michael V; Montaner Julio S G
The impact of adherence on CD4 cell count responses among HIV-infected patients.
Journal of acquired immune deficiency syndromes (1999) 2004;35(3):261-8.
2004: Montaner Julio S G; Côté Hélène C F; Harris Marianne; Hogg Robert S; Yip Benita; Harrigan P Richard; O'Shaughnessy Michael V
Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38 Suppl 2():S73-9.
2004: de la Rosa Rafael; Harris Marianne; Uyeda Linda; Goodison Karin; Keown Paul; Montaner Julio S G
Life-threatening reaction after first ever dose of abacavir in an HIV-1-infected patient.
AIDS (London, England) 2004;18(3):578-9.
2004: Montessori Valentina; Press Natasha; Harris Marianne; Akagi Linda; Montaner Julio S G
Adverse effects of antiretroviral therapy for HIV infection.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2004;170(2):229-38.
2003: O'Connell Jacqueline M; Braitstein Paula; Hogg Robert S; Yip Benito; Craib Kevin J P; O'Shaughnessy Michael V; Montaner Julio S G; Burdge David R
Age, adherence and injection drug use predict virological suppression among men and women enrolled in a population-based antiretroviral drug treatment programme.
Antiviral therapy 2003;8(6):569-76.
2003: Palepu Anita; Tyndall Mark W; Li Kathy; Yip Benita; O'Shaughnessy Michael V; Schechter Martin T; Montaner Julio S G; Hogg Robert S
Alcohol use and incarceration adversely affect HIV-1 RNA suppression among injection drug users starting antiretroviral therapy.
Journal of urban health : bulletin of the New York Academy of Medicine 2003;80(4):667-75.
2003: Wood Evan; Hogg Robert S; Heath Katherine V; de la Rosa Rafael; Lee Nelson; Yip Benita; O'Shaughnessy Michael V O; Montaner Julio S G
Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
AIDS (London, England) 2003;17(18):2629-34.
2003: Wood Evan; Hogg Robert S; Yip Benita; Quercia Romina; Harrigan P Richard; O'Shaughnessy Michael V; Montaner Julio S G
Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy.
The Journal of infectious diseases 2003;188(10):1421-5.
2003: Wood Evan; Hogg Robert S; Yip Benita; Harrigan P Richard; O'Shaughnessy Michael V; Montaner Julio S G
Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 x 10(9) cells/L.
Annals of internal medicine 2003;139(10):810-6.
2003: Wood Evan; Hogg Robert S; Yip Benita; O'Shaughnessy Michael V; Montaner Julio S G
CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
Journal of acquired immune deficiency syndromes (1999) 2003;34(3):347-8.
2003: Wood Evan; Montaner Julio S G; Bangsberg David R; Tyndall Mark W; Strathdee Steffanie A; O'Shaughnessy Michael V; Hogg Robert S
Expanding access to HIV antiretroviral therapy among marginalized populations in the developed world.
AIDS (London, England) 2003;17(17):2419-27.
2003: Delgado Juan; Heath Katherine V; Yip Benita; Marion Stephen; Alfonso Victoria; Montaner Julio S G; O'Shaughnessy Michael V; Hogg Robert S
Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill.
Antiviral therapy 2003;8(5):471-8.
2003: Harrigan P Richard; Hertogs Kurt; Verbiest Werner; Larder Brendan; Yip Benita; Brumme Zabrina L; Alexander Christopher; Tilley Jessica; O'Shaughnessy Michael V; Montaner Julio S G
Modest decreases in NNRTI susceptibility do not influence virological outcome in patients receiving initial NNRTI-containing triple therapy.
Antiviral therapy 2003;8(5):395-402.
2003: Bedell Richard; Heath Katherine V; Hogg Robert S; Wood Evan; Press Natasha; Yip Benita; O'Shaughnessy Michael V; Montaner Julio S G
Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.
Antiviral therapy 2003;8(5):379-84.
2003: Wood Evan; Montaner Julio S G; Tyndall Mark W; Schechter Martin T; O'Shaughnessy Michael V; Hogg Robert S
Prevalence and correlates of untreated human immunodeficiency virus type 1 infection among persons who have died in the era of modern antiretroviral therapy.
The Journal of infectious diseases 2003;188(8):1164-70.
2003: Montaner Julio S G; Côté Hélène C F; Harris Marianne; Hogg Robert S; Yip Benita; Chan Jennifer W; Harrigan P Richard; O'Shaughnessy Michael V
Mitochondrial toxicity in the era of HAART: evaluating venous lactate and peripheral blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2003;34 Suppl 1():S85-90.
2003: Wood Evan; Montaner Julio S G; Yip Benita; Tyndall Mark W; Schechter Martin T; O'Shaughnessy Michael V; Hogg Robert S
Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2003;169(7):656-61.
2003: Braitstein Paula; Yip Benita; Heath Katherine V; Levy Adrian R; Montaner Julio S; Humphries Karin; Kiely F Michael; O'Shaughnessy Michael V; Hogg Robert S
Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000.
AIDS (London, England) 2003;17(14):2071-5.
2003: Alexander Christopher S; Asselin Jérôme J; Ting Lillian S L; Montaner Julio S G; Hogg Robert S; Yip Benita; O'Shaughnessy Michael V; Harrigan P Richard
Antiretroviral concentrations in untimed plasma samples predict therapy outcome in a population with advanced disease.
The Journal of infectious diseases 2003;188(4):541-8.
2003: Lee Nelson; Hogg Robert S; Yip Benita; Harrigan P Richard; Harris Marianne; O'Shaughnessy Michael V; Montaner Julio S G
Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy.
The Journal of infectious diseases 2003;188(1):137-41.
2003: Montaner Julio S
Challenges of the unmet needs in the treatment-experienced patient.
The AIDS reader 2003;13(6 Suppl):S5-9.
2003: Côté Hélène C F; Yip Benita; Asselin Jérôme J; Chan Jennifer W; Hogg Robert S; Harrigan P Richard; O'Shaughnessy Michael V; Montaner Julio S G
Mitochondrial:nuclear DNA ratios in peripheral blood cells from human immunodeficiency virus (HIV)-infected patients who received selected HIV antiretroviral drug regimens.
The Journal of infectious diseases 2003;187(12):1972-6.
2003: Chan Kenny C; Galli Richard A; Montaner Julio S; Harrigan P Richard
Prolonged retention of drug resistance mutations and rapid disease progression in the absence of therapy after primary HIV infection.
AIDS (London, England) 2003;17(8):1256-8.
2003: Hicks Charles; Montaner Julio S G; Baker Ronald; Youle Michael
Selected topics from the 10th Conference on Retroviruses and Opportunistic Infections.
HIV clinical trials 2003;4(3):202-26.
2003: Montessori Valentina; Harris Marianne; Montaner Julio S G
Hepatotoxicity of nucleoside reverse transcriptase inhibitors.
Seminars in liver disease 2003;23(2):167-72.
2003: Montaner Julio S G; Cahn Pedro; Zala Carlos; Casssetti Lidia I; Losso Marcelo; Hall David B; Wruck Jan; McDonough Marita; Gigliotti Maria; Robinson Patrick A;
Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1.
Journal of acquired immune deficiency syndromes (1999) 2003;33(1):41-6.
2003: Hammond Emma L; Sayer David; Nolan David; Walker Ulrich A; Ronde Anthony de; Montaner Julio S G; Cote Helene C F; Gahan Michelle E; Cherry Catherine L; Wesselingh Steven L; Reiss Peter; Mallal Simon
Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2003;27(1):97-110.
2003: Lalezari Jacob P; Henry Keith; O'Hearn Mary; Montaner Julio S G; Piliero Peter J; Trottier Benôit; Walmsley Sharon; Cohen Calvin; Kuritzkes Daniel R; Eron Joseph J; Chung Jain; DeMasi Ralph; Donatacci Lucille; Drobnes Claude; Delehanty John; Salgo Miklos;
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
The New England journal of medicine 2003;348(22):2175-85.
2003: Brumme Zabrina L; Chan Keith J; Dong Winnie W Y; Wynhoven Brian; Mo Theresa; Hogg Robert S; Montaner Julio S G; O'Shaughnessy Michael V; Harrigan P Richard
Prevalence and clinical implications of insertions in the HIV-1 p6Gag N-terminal region in drug-naive individuals initiating antiretroviral therapy.
Antiviral therapy 2003;8(2):91-6.
2003: Palepu Anita; Tyndall Mark; Yip Benita; O'Shaughnessy Michael V; Hogg Robert S; Montaner Julio S G
Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use.
Journal of acquired immune deficiency syndromes (1999) 2003;32(5):522-6.
2003: Wood Evan; Hogg Robert S; Yip Benita; Harrigan P Richard; O'Shaughnessy Michael V; Montaner Julio S G
Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy?
AIDS (London, England) 2003;17(5):711-20.
2003: Brumme Zabrina L; Dong Winnie W Y; Chan Keith J; Hogg Robert S; Montaner Julio S G; O'Shaughnessy Michael V; Harrigan P Richard
Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response.
AIDS (London, England) 2003;17(2):201-8.
2003: Wood Evan; Tyndall Mark W; Spittal Patricia M; Li Kathy; Anis Aslam H; Hogg Robert S; Montaner Julio S G; O'Shaughnessy Michael V; Schechter Martin T
Impact of supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2003;168(2):165-9.
2003: Kijak G H; Rubio A E; Pampuro S E; Zala C; Cahn P; Galli R; Montaner J S; Salomón H
Discrepant results in the interpretation of HIV-1 drug-resistance genotypic data among widely used algorithms.
HIV medicine 2003;4(1):72-8.
2003: Heath K V; Montaner J S G; Bondy G; Singer J; O'Shaughnessy M V; Hogg R S
Emerging drug toxicities of highly active antiretroviral therapy for human immunodeficiency virus (HIV) infection.
Current drug targets 2003;4(1):13-22.
2002: Press Natasha; Tyndall Mark W; Wood Evan; Hogg Robert S; Montaner Julio S G
Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence.
Journal of acquired immune deficiency syndromes (1999) 2002;31 Suppl 3():S112-7.
2002: Zala Carlos; Harris Marianne; Ochoa Claudia; Tocci Mariel; Quercia Romina; Mittelman Graciela; Perez Héctor; Cahn Pedro; Montaner Julio S G
Venous and arterial blood lactate in HIV-infected patients.
Antiviral therapy 2002;7(4):309-10.
2002: Harris Marianne; Chan Keith J; Tesiorowski Alicja M; Hogg Robert S; Rosenberg Frances M; Yan Clifford Chan; Montaner Julio S G
Random venous lactate levels among HIV-positive patients on antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2002;31(4):448-50.
2002: Heath Katherine V; Chan Keith J; Singer Joel; O'Shaughnessy Michael V; Montaner Julio S G; Hogg Robert S
Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.
International journal of epidemiology 2002;31(5):1016-20.
2002: Tesiorowski Alicja M; Harris Marianne; Chan Keith J; Thompson Christopher R; Montaner Julio S G
Anaerobic threshold and random venous lactate levels among HIV-positive patients on antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2002;31(2):250-1.
2002: Heath Katherine V; Singer Joel; O'Shaughnessy Michael V; Montaner Julio S G; Hogg Robert S
Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2002;31(2):211-7.
2002: Wood Evan; Montaner Julio S G; Chan Keith; Tyndall Mark W; Schechter Martin T; Bangsberg David; O'Shaughnessy Michael V; Hogg Robert S
Socioeconomic status, access to triple therapy, and survival from HIV-disease since 1996.
AIDS (London, England) 2002;16(15):2065-72.
2002: Brumme Zabrina L; Chan Keith J; Dong Winnie W; Mo Theresa; Wynhoven Brian; Hogg Robert S; Montaner Julio S; O'Shaughnessy Michael V; Harrigan P Richard
No association between GB virus-C viremia and virological or immunological failure after starting initial antiretroviral therapy.
AIDS (London, England) 2002;16(14):1929-33.
2002: Miller Cari L; Johnston Caitlin; Spittal Patricia M; Li Kathy; Laliberté Nancy; Montaner Julio S G; Schechter Martin T
Opportunities for prevention: hepatitis C prevalence and incidence in a cohort of young injection drug users.
Hepatology (Baltimore, Md.) 2002;36(3):737-42.
2002: Chan Kenny C W; Yip Benita; Hogg Robert S; Montaner Julio S G; O'Shaughnessy Michael V
Survival rates after the initiation of antiretroviral therapy stratified by CD4 cell counts in two cohorts in Canada and the United States.
AIDS (London, England) 2002;16(12):1693-5.
2002: Raboud Janet M; Rae Sandra; Woods Ryan; Harris Marianne; Montaner Julio S G;
Consecutive rebounds in plasma viral load are associated with virological failure at 52 weeks among HIV-infected patients.
AIDS (London, England) 2002;16(12):1627-32.
2002: Heath Katherine V; Hogg Robert S; Singer Joel; Chan Keith J; O'Shaughnessy Michael V; Montaner Julio S G
Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.
Journal of acquired immune deficiency syndromes (1999) 2002;30(4):440-7.
2002: Rekart Michael L; Krajden Mel; Cook Darrel; McNabb Gail; Rees Tony; Isaac-Renton Judy; Harris Marianne; Montaner Julio S G
Problems with the fast-check HIV rapid test kits.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2002;167(2):119.
2002: Yeni Patrick G; Hammer Scott M; Carpenter Charles C J; Cooper David A; Fischl Margaret A; Gatell Jose M; Gazzard Brian G; Hirsch Martin S; Jacobsen Donna M; Katzenstein David A; Montaner Julio S G; Richman Douglas D; Saag Michael S; Schechter Mauro; Schooley Robert T; Thompson Melanie A; Vella Stefano; Volberding Paul A
Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2002;288(2):222-35.
2002: Wood Evan; Hogg Robert S; Yip Benita; Tyndall Mark W; Sherlock Christopher H; Harrigan Richard P; O'Shaughnessy Michael V; Montaner Julio S G
"Discordant" increases in CD4 cell count relative to plasma viral load in a closely followed cohort of patients initiating antiretroviral therapy.
Journal of acquired immune deficiency syndromes (1999) 2002;30(2):159-66.
2002: Harris Marianne; Back David; Kewn Sean; Jutha Salima; Marina Raymond; Montaner Julio S G
Intracellular carbovir triphosphate levels in patients taking abacavir once a day.
AIDS (London, England) 2002;16(8):1196-7.
2002: Braitstein Paula; Chan Keith; Beardsell Ann; McLeod Alistair; Montaner Julio S G; O'Shaughnessy Michael V; Hogg Robert S
Prescribing practices in a population-based HIV postexposure prophylaxis program.
AIDS (London, England) 2002;16(7):1067-70.
2002: Hogg Robert S; Heath Katherine; Bangsberg David; Yip Benita; Press Natasha; O'Shaughnessy Michael V; Montaner Julio S G
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.
AIDS (London, England) 2002;16(7):1051-8.
2002: Raboud J M; Harris M; Rae S; Montaner J S G
Impact of adherence on duration of virological suppression among patients receiving combination antiretroviral therapy.
HIV medicine 2002;3(2):118-24.
2002: Braitstein Paula; Chan Keith; Beardsell Ann; McLeod Alistair; Montaner Julio S G; O'Shaughnessy Michael V; Hogg Robert S
Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):547-8.
2002: Wood Evan; Tyndall Mark W; Spittal Patricia M; Li Kathy; Hogg Robert S; Montaner Julio S G; O'Shaughnessy Michael V; Schechter Martin T
Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme.
AIDS (London, England) 2002;16(6):941-3.
2002: Zala Carlos; Salomon Horacio; Ochoa Claudia; Kijak Gustavo; Federico Andrea; Perez Héctor; Montaner Julio S G; Cahn Pedro
Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2002;29(4):368-73.
2002: Alexander Christopher S; Montessori Valentina; Wynhoven Brian; Dong Winnie; Chan Keith; O'Shaughnessy Michael V; Mo Theresa; Piaseczny Magda; Montaner Julio S G; Harrigan P Richard
Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia.
Antiviral therapy 2002;7(1):31-5.
2002: Harris Marianne; Alexander Chris; O'Shaughnessy Michael; Montaner Julio S G
Delavirdine increases drug exposure of ritonavir-boosted protease inhibitors.
AIDS (London, England) 2002;16(5):798-9.
2002: Hogg Robert S; Havlir Diane; Miller Veronica; Montaner Julio S G
To stop or not to stop: that is the question, but what is the answer?
AIDS (London, England) 2002;16(5):787-9.
2002: Côté Hélène C F; Brumme Zabrina L; Craib Kevin J P; Alexander Christopher S; Wynhoven Brian; Ting Lillian; Wong Hubert; Harris Marianne; Harrigan P Richard; O'Shaughnessy Michael V; Montaner Julio S G
Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients.
The New England journal of medicine 2002;346(11):811-20.
2002: Press Natasha; Kimel Gil; Harris Marianne; Yip Benita; Craib Kevin J P; Montaner Julio S G
Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimens.
HIV clinical trials 2002;3(1):17-20.
2002: Grant Michael; Pardoe Ingrid; Whaley Mark; Montaner Julio S G; Harrigan P Richard
The T cell receptor V beta repertoire shows little change during treatment interruption-related viral rebound in chronic HIV infection.
AIDS (London, England) 2002;16(2):287-90.
2001: Montaner J S; O'Shaughnessy M V; Schechter M T
Industry-sponsored clinical research: a double-edged sword.
Lancet 2001;358(9296):1893-5.
2001: Hogg R S; Yip B; Chan K J; Wood E; Craib K J; O'Shaughnessy M V; Montaner J S
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
JAMA : the journal of the American Medical Association 2001;286(20):2568-77.
2001: Braitstein P; Chan K; Beardsell A; McLeod A; Montaner J S; O'Shaughnessy M V; Hogg R S
Another reality check: the direct costs of providing post-exposure prophylaxis in a population-based programme.
AIDS (London, England) 2001;15(17):2345-7.
2001: Brumme Z L; Chan K J; Dong W; Hogg R; O'Shaughnessy M V; Montaner J S; Harrigan P R
CCR5Delta32 and promoter polymorphisms are not correlated with initial virological or immunological treatment response.
AIDS (London, England) 2001;15(17):2259-66.
2001: Harrigan P R; Montaner J S; Wegner S A; Verbiest W; Miller V; Wood R; Larder B A
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.
AIDS (London, England) 2001;15(13):1671-7.
2001: Wood E; Tyndall M W; Spittal P M; Li K; Kerr T; Hogg R S; Montaner J S; O'Shaughnessy M V; Schechter M T
Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help?
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2001;165(4):405-10.
2001: Conway B; Wainberg M A; Hall D; Harris M; Reiss P; Cooper D; Vella S; Curry R; Robinson P; Lange J M; Montaner J S
Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.
AIDS (London, England) 2001;15(10):1269-74.
2001: Alexander C S; Dong W; Chan K; Jahnke N; O'Shaughnessy M V; Mo T; Piaseczny M A; Montaner J S; Harrigan P R
HIV protease and reverse transcriptase variation and therapy outcome in antiretroviral-naive individuals from a large North American cohort.
AIDS (London, England) 2001;15(5):601-7.
2001: Braitstein P; Kendall T; Chan K; Wood E; Montaner J S; O'Shaughnessy M V; Hogg R S
Mary-Jane and her patients: sociodemographic and clinical characteristics of HIV-positive individuals using medical marijuana and antiretroviral agents.
AIDS (London, England) 2001;15(4):532-3.
2001: Palepu A; Yip B; Miller C; Strathdee S A; O'Shaughnessy M V; Montaner J S; Hogg R S
Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use.
AIDS (London, England) 2001;15(3):423-4.
2001: Montaner J S; Harrigan P R; Jahnke N; Raboud J; Castillo E; Hogg R S; Yip B; Harris M; Montessori V; O'Shaughnessy M V
Multiple drug rescue therapy for HIV-infected individuals with prior virologic failure to multiple regimens.
AIDS (London, England) 2001;15(1):61-9.
2000: Anis A H; Guh D; Hogg R S; Wang X H; Yip B; Craib K J; O'Shaughnessy M V; Schechter M T; Montaner J S
The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS.
PharmacoEconomics 2000;18(4):393-404.
2000: Zala C; Ochoa C; Krolewiecki A; Patterson P; Cahn P; Crawford R I; Montaner J S
Highly active antiretroviral therapy does not protect against Kaposi's sarcoma in HIV-infected individuals.
AIDS (London, England) 2000;14(14):2217-8.
2000: Wood E; Yip B; Hogg R S; Sherlock C H; Jahnke N; Harrigan R P; O'Shaughnessy M V; Montaner J S
Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy.
AIDS (London, England) 2000;14(13):1955-60.
2000: Wood E; Chan K; Montaner J S; Schechter M T; Tyndall M; O'Shaughnessy M V; Hogg R S
The end of the line: has rapid transit contributed to the spatial diffusion of HIV in one of Canada's largest metropolitan areas?
Social science & medicine (1982) 2000;51(5):741-8.
2000: Raboud J M; Rae S; Montaner J S
Predicting HIV RNA virologic outcome at 52-weeks follow-up in antiretroviral clinical trials. The INCAS and AVANTI Study Groups.
Journal of acquired immune deficiency syndromes (1999) 2000;24(5):433-9.
2000: Montessori V; Rouleau D; Raboud J; Rae S; Woo I; Montaner J S; Conway B
Clinical characteristics of primary HIV infection in injection drug users.
AIDS (London, England) 2000;14(12):1868-70.
2000: Wood E; Braitstein P; Montaner J S; Schechter M T; Tyndall M W; O'Shaughnessy M V; Hogg R S
Extent to which low-level use of antiretroviral treatment could curb the AIDS epidemic in sub-Saharan Africa.
Lancet 2000;355(9221):2095-100.
2000: Wood E; Schechter M T; Tyndall M W; Montaner J S; O'Shaughnessy M V; Hogg R S
Antiretroviral medication use among injection drug users: two potential futures.
AIDS (London, England) 2000;14(9):1229-35.
2000: Zala C; Rouleau D; Montaner J S
Role of hydroxyurea in treatment of disease due to human immunodeficiency virus infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2000;30 Suppl 2():S143-50.
2000: Low-Beer S; Yip B; O'Shaughnessy M V; Hogg R S; Montaner J S
Adherence to triple therapy and viral load response.
Journal of acquired immune deficiency syndromes (1999) 2000;23(4):360-1.
2000: Low-Beer S; Chan K; Yip B; Wood E; Montaner J S; O'Shaughnessy M V; Hogg R S
Depressive symptoms decline among persons on HIV protease inhibitors.
Journal of acquired immune deficiency syndromes (1999) 2000;23(4):295-301.
2000: Weber A E; Yip B; O'Shaughnessy M V; Montaner J S; Hogg R S
Determinants of hospital admission among HIV-positive people in British Columbia.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2000;162(6):783-6.
2000: Wood E; Yip B; Gataric N; Montaner J S; O'Shaughnessy M V; Schechter M T; Hogg R S
Determinants of geographic mobility among participants in a population-based HIV/AIDS drug treatment program.
Health & place 2000;6(1):33-40.
2000: Low-Beer S; Weber A E; Bartholomew K; Landolt M; Oram D; Montaner J S; O'Shaughnessy M V; Hogg R S
A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk.
AIDS (London, England) 2000;14(3):325-6.
2000: Montaner J S; Mo T; Raboud J M; Rae S; Alexander C S; Zala C; Rouleau D; Harrigan P R
Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
The Journal of infectious diseases 2000;181(2):729-32.
2000: Cornelisse P G; Montessori V; Yip B; Craib K J; O'Shaughnessy M V; Montaner J S; Hogg R S
The impact of zidovudine on dementia-free survival in a population of HIV-positive men and women on antiretroviral therapy.
International journal of STD & AIDS 2000;11(1):52-6.
2000: Carpenter C C; Cooper D A; Fischl M A; Gatell J M; Gazzard B G; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Saag M S; Schechter M; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 2000;283(3):381-90.
2000: Low-Beer S; Chan K; Wood E; Yip B; Montaner J S; O'Shaughnessy M V; Hogg R S
Health related quality of life among persons with HIV after the use of protease inhibitors.
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation 2000;9(8):941-9.
1999: Raboud J M; Rae S; Vella S; Harrigan P R; Bucciardini R; Fragola V; Ricciardulli D; Montaner J S
Meta-analysis of two randomized controlled trials comparing combined zidovudine and didanosine therapy with combined zidovudine, didanosine, and nevirapine therapy in patients with HIV. INCAS study team.
Journal of acquired immune deficiency syndromes (1999) 1999;22(3):260-6.
1999: Harrigan P R; Hertogs K; Verbiest W; Pauwels R; Larder B; Kemp S; Bloor S; Yip B; Hogg R; Alexander C; Montaner J S
Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting.
AIDS (London, England) 1999;13(14):1863-71.
1999: Raboud J M; Rae S; Hogg R S; Yip B; Sherlock C H; Harrigan P R; O'Shaughnessy M V; Montaner J S
Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation.
The Journal of infectious diseases 1999;180(4):1347-50.
1999: Jahnke N; Yip B; Hogg R S; O'Shaughnessy M; Montaner J S
Antiviral effect of AZT versus stavudine in combination with lamivudine and indinavir in the context of a populational study.
Journal of acquired immune deficiency syndromes (1999) 1999;21(4):347-8.
1999: Alexander C S; Dong W; Schechter M T; O'Shaughnessy M V; Strathdee S A; Mo T; Montaner J S; Harrigan P R
Prevalence of primary HIV drug resistance among seroconverters during an explosive outbreak of HIV infection among injecting drug users.
AIDS (London, England) 1999;13(8):981-5.
1999: Harrigan P R; Whaley M; Montaner J S
Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy.
AIDS (London, England) 1999;13(8):F59-62.
1999: Montaner J S
Induction/maintenance treatment regimens for HIV.
JAMA : the journal of the American Medical Association 1999;281(18):1680-2.
1999: Conway B; Montessori V; Rouleau D; Montaner J S; O'Shaughnessy M V; Fransen S; Shillington A; Weislow O; Mayers D L
Primary lamivudine resistance in acute/early human immunodeficiency virus infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;28(4):910-1.
1999: Forrest D M; Zala C; Djurdjev O; Singer J; Craib K J; Lawson L; Russell J A; Montaner J S
Determinants of short- and long-term outcome in patients with respiratory failure caused by AIDS-related Pneumocystis carinii pneumonia.
Archives of internal medicine 1999;159(7):741-7.
1999: Montaner J S; Montessori V; Harrigan R; O'Shaughnessy M; Hogg R
Antiretroviral therapy: 'the state of the art'.
Biomedicine & pharmacotherapy = Biomédecine & pharmacothérapie 1999;53(2):63-72.
1999: Pakker N G; Kroon E D; Roos M T; Otto S A; Hall D; Wit F W; Hamann D; van der Ende M E; Claessen F A; Kauffmann R H; Koopmans P P; Kroon F P; ten Napel C H; Sprenger H G; Weigel H M; Montaner J S; Lange J M; Reiss P; Schellekens P T; Miedema F
Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. INCAS Study Group.
AIDS (London, England) 1999;13(2):203-12.
1999: Jahnke N; Seminari E; Hogg R S; Yip B; O'Shaughnessy M V; Montaner J S
Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based setting.
Antiviral therapy 1999;4(3):151-6.
1998: Forrest D M; Seminari E; Hogg R S; Yip B; Raboud J; Lawson L; Phillips P; Schechter M T; O'Shaughnessy M V; Montaner J S
The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;27(6):1379-85.
1998: Montaner J S; Hogg R; Raboud J; Harrigan R; O'Shaughnessy M
Antiretroviral treatment in 1998.
Lancet 1998;352(9144):1919-22.
1998: Hogg R S; Weber A E; Craib K J; Anis A H; O'Shaughnessy M V; Schechter M T; Montaner J S
One world, one hope: the cost of providing antiretroviral therapy to all nations.
AIDS (London, England) 1998;12(16):2203-9.
1998: Rae S; Raboud J M; Conway B; Reiss P; Vella S; Cooper D; Lange J; Harris M; Wainberg M A; Robinson P; Myers M; Hall D; Montaner J S
Estimates of the virological benefit of antiretroviral therapy are both assay- and analysis-dependent.
AIDS (London, England) 1998;12(16):2185-92.
1998: Raboud J M; Seminari E; Rae S L; Harrigan P R; Hogg R S; Conway B; Sherlock C; Schechter M T; O'Shaughnessy M V; Montaner J S
Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays.
Journal of clinical microbiology 1998;36(11):3369-71.
1998: Montaner J S; Raboud J; Rae S; Vella S
British HIV Association guidelines.
Lancet 1998;352(9135):1226-7.
1998: Raboud J M; Montaner J S; Conway B; Rae S; Reiss P; Vella S; Cooper D; Lange J; Harris M; Wainberg M A; Robinson P; Myers M; Hall D
Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy.
AIDS (London, England) 1998;12(13):1619-24.
1998: Veugelers P J; Cornelisse P G; Craib K J; Marion S A; Hogg R S; Strathdee S A; Montaner J S; O'Shaughnessy M V; Schechter M T
Models of survival in HIV infection and their use in the quantification of treatment benefits.
American journal of epidemiology 1998;148(5):487-96.
1998: Strathdee S A; Hogg R S; Martindale S L; Cornelisse P G; Craib K J; Montaner J S; O'Shaughnessy M V; Schechter M T
Determinants of sexual risk-taking among young HIV-negative gay and bisexual men.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;19(1):61-6.
1998: Rhone S A; Hogg R S; Yip B; Sherlock C; Conway B; Schechter M T; O'Shaughnessy M V; Montaner J S
Do dual nucleoside regimens have a role in an era of plasma viral load-driven antiretroviral therapy?
The Journal of infectious diseases 1998;178(3):662-8.
1998: Heath K V; Frank O; Montaner J S; O'Shaughnessy M V; Schechter M T; Hogg R S
Human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS) mortality in industrialized nations, 1987-1991.
International journal of epidemiology 1998;27(4):685-90.
1998: Strathdee S A; Palepu A; Cornelisse P G; Yip B; O'Shaughnessy M V; Montaner J S; Schechter M T; Hogg R S
Barriers to use of free antiretroviral therapy in injection drug users.
JAMA : the journal of the American Medical Association 1998;280(6):547-9.
1998: Forrest D M; Djurdjev O; Zala C; Singer J; Lawson L; Russell J A; Montaner J S
Validation of the modified multisystem organ failure score as a predictor of mortality in patients with AIDS-related Pneumocystis carinii pneumonia and respiratory failure.
Chest 1998;114(1):199-206.
1998: Carpenter C C; Fischl M A; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Saag M S; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel.
JAMA : the journal of the American Medical Association 1998;280(1):78-86.
1998: Anis A H; Hogg R S; Wang X H; Yip B; Palepu A; Montaner J S; O'Shaughnessy M V; Schechter M T
Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.
PharmacoEconomics 1998;13(6):697-705.
1998: Harris M; Durakovic C; Rae S; Raboud J; Fransen S; Shillington A; Conway B; Montaner J S
A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy.
The Journal of infectious diseases 1998;177(6):1514-20.
1998: Rhone S A; Hogg R S; Yip B; Sherlock C; Conway B; Schechter M T; O'Shaughnessy M V; Montaner J S
The antiviral effect of ritonavir and saquinavir in combination amongst HIV-infected adults: results from a community-based study.
AIDS (London, England) 1998;12(6):619-24.
1998: Tsoukas C M; Raboud J; Bernard N F; Montaner J S; Gill M J; Rachlis A; Fong I W; Schlech W; Djurdjev O; Freedman J; Thomas R; Lafrenière R; Wainberg M A; Cassol S; O'Shaughnessy M; Todd J; Volvovitz F; Smith G E
Active immunization of patients with HIV infection: a study of the effect of VaxSyn, a recombinant HIV envelope subunit vaccine, on progression of immunodeficiency.
AIDS research and human retroviruses 1998;14(6):483-90.
1998: Montaner J S; DeMasi R; Hill A M
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
AIDS (London, England) 1998;12(5):F23-8.
1998: Hogg R S; Rhone S A; Yip B; Sherlock C; Conway B; Schechter M T; O'Shaughnessy M V; Montaner J S
Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.
AIDS (London, England) 1998;12(3):279-84.
1998: Hogg R S; Raboud J; Bigham M; Montaner J S; O'Shaughnessy M; Schechter M T
Relation between hospital HIV/AIDS caseload and mortality among persons with HIV/AIDS in Canada.
Clinical and investigative medicine. Médecine clinique et experimentale 1998;21(1):27-32.
1998: Hogg R S; Heath K V; Yip B; Craib K J; O'Shaughnessy M V; Schechter M T; Montaner J S
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy.
JAMA : the journal of the American Medical Association 1998;279(6):450-4.
1998: Montaner J S; Shillington A; Gonzalez Montaner L J
HIV/AIDS treatment: lessons from the tuberculosis experience.
Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 1998;1(3):157-60.
1998: Salomon H; Montaner J S; Belmonte A; Wainberg M A
Diminished HIV-1 sensitivity to stavudine in patients on prolonged therapy occurs only at low levels and cannot be attributed to any single amino acid substitution in reverse transcriptase.
Antiviral therapy 1998;3(3):177-82.
1997: Raboud J M; Montaner J S; Rae S; Kahn J; Hammer S M; Katzenstein D A; Pavia A; Dolin R; Hughes M D; Cross A; Beltangady M; Gatell J; Dunkle L; Smaldone L
Meta-analysis of five randomized controlled trials comparing continuation of zidovudine versus switching to didanosine in HIV-infected individuals.
Antiviral therapy 1997;2(4):237-47.
1997: Heath K V; Hogg R S; Singer J; Schechter M T; O'Shaughnessy M V; Montaner J S
Adherence to clinical guidelines for the therapeutic management of HIV disease.
Clinical and investigative medicine. Médecine clinique et experimentale 1997;20(6):381-7.
1997: Heath K; Hogg R S; Raboud J; Montaner J S; O'Shaughnessy M; Schechter M T
Gender differentials in patterns of hospitalization for persons with HIV/AIDS.
AIDS (London, England) 1997;11(14):1788-9.
1997: Harris M; Patenaude P; Cooperberg P; Filipenko D; Thorne A; Raboud J; Rae S; Dailey P; Chernoff D; Todd J; Conway B; Montaner J S
Correlation of virus load in plasma and lymph node tissue in human immunodeficiency virus infection. INCAS Study Group. Italy, Netherlands, Canada, Australia, and (United) States.
The Journal of infectious diseases 1997;176(5):1388-92.
1997: Rouleau D; Conway B; Raboud J; Rae S; Fransen S; Shillington A; Zala C; O'Shaughnessy M V; Montaner J S
Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study.
The Journal of infectious diseases 1997;176(5):1156-60.
1997: Heath K; Hogg R S; Singer J; Schechter M T; O'Shaughnessy M V; Montaner J S
Physician concurrence with primary care guidelines for persons with HIV disease.
International journal of STD & AIDS 1997;8(10):609-13.
1997: Craib K J; Strathdee S A; Hogg R S; Leung B; Montaner J S; O'Shaughnessy M V; Schechter M T
Serum levels of human immunodeficiency virus type 1 (HIV-1) RNA after seroconversion: a predictor of long-term mortality in HIV infection.
The Journal of infectious diseases 1997;176(3):798-800.
1997: Strathdee S A; Patrick D M; Currie S L; Cornelisse P G; Rekart M L; Montaner J S; Schechter M T; O'Shaughnessy M V
Needle exchange is not enough: lessons from the Vancouver injecting drug use study.
AIDS (London, England) 1997;11(8):F59-65.
1997: Ostrow M J; Cornelisse P G; Heath K V; Craib K J; Schechter M T; O'Shaughnessy M; Montaner J S; Hogg R S
Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;15(2):115-20.
1997: Hogg R S; Strathdee S A; Craib K J; O'Shaughnessy M V; Montaner J S; Schechter M T
Modelling the impact of HIV disease on mortality in gay and bisexual men.
International journal of epidemiology 1997;26(3):657-61.
1997: Carpenter C C; Fischl M A; Hammer S M; Hirsch M S; Jacobsen D M; Katzenstein D A; Montaner J S; Richman D D; Saag M S; Schooley R T; Thompson M A; Vella S; Yeni P G; Volberding P A
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel.
JAMA : the journal of the American Medical Association 1997;277(24):1962-9.
1997: Montaner J S; Hogg R S; O'Shaughnessy M V
Emerging international consensus for use of antiretroviral therapy.
Lancet 1997;349(9058):1042.
1997: Montaner J S; Zala C; Conway B; Raboud J; Patenaude P; Rae S; O'Shaughnessy M V; Schechter M T
A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.
The Journal of infectious diseases 1997;175(4):801-6.
1997: Raboud J M; Montaner J S; Rae S; Conway B; Singer J; Schechter M T
Issues in the design of trials of therapies for subjects with human immunodeficiency virus infection that use plasma RNA level as an outcome.
The Journal of infectious diseases 1997;175(3):576-82.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Julio Montaner

Research Profile (preview)

Disorders

Chemicals & Drugs

Procedures

Geographic Areas

Concepts & Ideas

Living Beings

Activities & Behaviors

Physiology

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Julio Montaner (preview)

All Publications